Skip to main content
Fig. 7 | Journal of Biomedical Science

Fig. 7

From: Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo

Fig. 7

Antitumor effects of NEO212 in vivo. Tumor-bearing animals received vehicle or 30 mg/kg NEO212, given by subcutaneous injection into the neck area (distal to the site of tumor location in the flank), once daily over the course of 10 days. Twelve days after termination of treatment, tumor growth was compared among all animals via whole-body bioluminescent imaging. a, Shown is the relative change in bioluminescent radiance for each animal from the time treatment was started (set at 1.0) until 22 days later. Animals 1 through 6 had received vehicle only, whereas animals 11 through 16 had received NEO212. b, Two individual animals are shown as examples: one animal (#4) from the vehicle-treated group and one animal (#3) from the NEO212-treated group. Animal #13 (similar to animals 11 and 12) presented with undetectable tumor. The difference in bioluminescent radiance between the group of NEO212-treated animals and the group of vehicle-treated animals was statistically significant (p > 0.01)

Back to article page